A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Kraig Biocraft Laboratories, Inc.
KBLB
$70M
Mkt Cap
$0.09
-3.22%
Kraig Biocraft Laboratories, Inc. (KBLB) has a 5-year average return on invested capital (ROIC) of -91.3%. This is below average and may indicate limited pricing power.
Kraig Biocraft Laboratories, Inc. (KBLB) has a market capitalization of $94M. It is classified as a small-cap stock.
Kraig Biocraft Laboratories, Inc. (KBLB) does not currently pay a regular dividend.
Kraig Biocraft Laboratories, Inc. (KBLB) operates in the Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) industry, within the Materials sector.
Kraig Biocraft Laboratories, Inc. (KBLB) generated $-2 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Kraig Biocraft Laboratories, Inc. (KBLB) reported earnings per share (EPS) of $-0.01 in its most recent fiscal year.
The Ledger Terminal provides 9 years of financial data for Kraig Biocraft Laboratories, Inc. (KBLB), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ITEM 1. DESCRIPTION OF BUSINESS. Kraig Biocraft Laboratories, Inc., a Wyoming corporation, is a corporation organized to develop high strength fibers using recombinant DNA technology for commercial applications including technical textiles. We use genetically engineered silkworms that produce spider silk proteins to create our recombinant spider silk. Applications include performance apparel, workwear, filtration, luxury fashion, flexible composites, medical implants, cosmetics and more. We believe that we are a world leader in the research, development, and production of commercially scalable and cost-effective spider silk fiber. Our primary proprietary fiber technology utilizes natural and engineered variants of spider silk produced in domesticated mulberry silkworms. Our business brings twenty-first century biotechnology to the historical silk industry.
| Metric | TTM | FY2021 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | 0 |
| Net Income | -3.7M | -8.0M | -1.2M | -2.3M | -3.1M | -2.1M |
| EPS | $0.00 | $-0.01 | $-0.00 | $0.00 | $0.00 | $0.00 |
| Free Cash Flow | 0 | -1.9M | -246K | -761K | -1.0M | -1.0M |
| ROIC | -112.9% | -91.3% | -1062.4% | -1487.6% | -606.5% | -532.3% |
| Gross Margin | - | 0.0% | - | - | - | - |
| Debt/Equity | 0.00 | -0.43 | -0.14 | -0.05 | -0.04 | -0.00 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | - |
| Operating Income | -3.4M | -2.8M | -960K | -2.2M | -2.9M | -2.1M |
| Operating Margin | 0.0% | 0.0% | - | - | - | - |
| ROE | 0.0% | 0.0% | - | - | - | - |
| Shares Outstanding | 1,081M | 805M | 844M | 836M | 817M | 781M |
| Metric | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | N/A |
| R&D | 251K | 465K | 489K | 440K | 432K | 397K | 259K | 148K | 198K | 158K |
| SG&A | 787K | 379K | 1.3M | 896K | 921K | 1.7M | 1.2M | 516K | 1.5M | 2.1M |
| EBIT | -1.3M | -1.6M | -2.2M | -1.8M | -2.1M | -2.9M | -2.2M | -960K | -2.8M | -3.4M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Net Income | -1.3M | -1.6M | -7.5M | -1.9M | -2.1M | -3.1M | -2.3M | -1.2M | -8.0M | -3.7M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||||
| ROIC | N/M | N/M | N/M | N/M | N/M | N/M | N/M | N/M | -91.3% | -112.9% |
| ROE | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| ROA | -579.6% | -2035.4% | -2399.5% | -347.3% | -699.7% | -801.2% | -2037.7% | -1637.6% | -374.3% | -156.5% |
| Cash Flow | ||||||||||
| Op. Cash Flow | -556K | -563K | -800K | -905K | -968K | -1.0M | -730K | -235K | -1.8M | -1.9M |
| Free Cash Flow | -557K | -563K | -804K | -946K | -1.0M | -1.0M | -761K | -246K | -1.9M | 0 |
| Owner Earnings | -873K | -1.1M | -2.3M | -912K | -983K | -1.0M | -750K | -262K | -1.8M | -1.9M |
| CapEx | 1K | 0 | 3K | 42K | 39K | 2K | 31K | 11K | 97K | 0 |
| Maint. CapEx | 5K | 6K | 6K | 7K | 15K | 17K | 20K | 27K | 26K | 24K |
| Growth CapEx | 0 | N/A | 0 | 35K | 24K | 0 | 11K | 0 | 71K | 0 |
| D&A | 5K | 6K | 6K | 7K | 15K | 17K | 20K | 27K | 26K | 24K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 312K | 550K | 1.5M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50K | 50K |
| Balance Sheet | ||||||||||
| Net Debt | -386K | -94K | -587K | N/A | -476K | -498K | 124K | 617K | -2.5M | -1.6M |
| Cash & Equiv. | 195K | 54K | 295K | 495K | 238K | 299K | 18K | 14K | 2.4M | 3.1M |
| Long-Term Debt | N/A | 9K | N/A | N/A | N/A | N/A | N/A | N/A | 95K | 95K |
| Debt/Equity | -0.01 | -0.01 | -0.00 | -1.44 | 0.00 | -0.04 | -0.05 | -0.14 | -0.43 | 0.00 |
| Interest Coverage | N/A | -34.1 | -33.8 | -26.5 | -20.2 | -21.1 | -12.2 | -4.2 | -4.2 | -4.2 |
| Equity | -906K | -1.1M | -1.2M | -1.2M | -1.9M | -2.4M | -3.4M | -4.5M | -5.3M | -8.0M |
| Total Assets | 224K | 79K | 311K | 539K | 305K | 384K | 114K | 71K | 3.0M | 2.4M |
| Total Liabilities | 1.1M | 1.2M | 1.5M | 1.8M | 2.2M | 2.7M | 3.5M | 4.5M | 8.3M | 10M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 | 0 |
| Retained Earnings | N/A | N/A | N/A | -18M | -20M | -23M | -26M | -27M | -43M | -56M |
| Working Capital | -915K | -1.1M | -1.2M | -1.3M | -2.0M | -2.4M | -3.4M | -4.5M | -5.8M | -8.5M |
| Current Assets | 201K | 62K | 297K | 496K | 239K | 332K | 48K | 21K | 2.4M | 1.6M |
| Current Liabilities | 1.1M | 1.2M | 1.5M | 1.8M | 2.2M | 2.7M | 3.5M | 4.5M | 8.2M | 10M |
| Per Share Data | ||||||||||
| EPS | -0.00 | -0.00 | -0.01 | -0.00 | 0.00 | 0.00 | 0.00 | -0.00 | -0.01 | 0.00 |
| Owner EPS | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Book Value | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 |
| Cash Flow/Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.00 |
| Shares Out. | 605.2M | 654.6M | 746.8M | 719.1M | 781.0M | 816.8M | 835.7M | 844.5M | 804.6M | 1.1B |
| Valuation | ||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -1.3% | -2.1% | -2.2% | -3.3% | -6.4% | -2.5% | -2.3% | -0.6% | N/A | N/A |
| Market Cap | 42M | 26M | 37M | 29M | 16M | 41M | 33M | 42M | 0 | 94M |
| Avg. Price | 0.10 | 0.06 | 0.07 | 0.05 | 0.03 | 0.04 | 0.06 | 0.05 | 0.00 | 0.09 |
| Year-End Price | 0.07 | 0.04 | 0.05 | 0.04 | 0.02 | 0.05 | 0.04 | 0.05 | 0.00 | 0.09 |
Kraig Biocraft Laboratories, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Kraig Biocraft Laboratories, Inc. (KBLB) has a book value per share of $-0.01, based on its most recent annual SEC filing.